Table 1.
Case information.
| Case number | Sex | Age | PMI, h | Braak stage | Aβ plaque A39/40 | Diagnoses | Figures using case |
|---|---|---|---|---|---|---|---|
| Alzheimer’s disease | |||||||
| 11-09 | M | 77 | 5.5 | VI | Moderate | AD/atherosclerosis/CAA | Figs. 1d and 2a, b |
| 11-17 | F | 69 | 3.6 | VI | Frequent | AD/CAA | Fig. 2d |
| 12-12 | F | 82 | 7 | VI | Frequent | AD | Fig. 5 (AD8) |
| 12-13 | F | 95 | 6.2 | VI | Frequent | AD/CAA/vascular dementia | Fig. 4 |
| 13-14 | F | 63 | 6.5 | VI | Frequent | AD/hippocampal sclerosis/CAA | Fig. 4 |
| 16-12 | F | ≥90 | 5.16 | VI | Moderate | AD/CAA | Fig. 2a, b |
| 16-15 | F | 55 | 5.57 | VI | Frequent | AD/arteriolar sclerosis/CAA/hippocampal sclerosis | Fig. 3d |
| 17-18 | M | 81 | 6.58 | VI | Moderate | AD/atherosclerosis/CAA/vascular dementia | Fig. 4 |
| 2-12 | F | 64 | 5.3 | V | Frequent | AD/CAA | Fig. 2a, b |
| 21-11 | M | 96 | 5.4 | VI | Frequent | AD/atherosclerotic leukoencephalopathy/arterial sclerosis/CAA/hippocampal sclerosis | Fig. 4 |
| 21-12 | M | 90 | 3.5 | V | Moderate | AD/atherosclerosis/hippocampal sclerosis | Fig. 4 |
| 21-17 | M | ≥90 | 5.32 | V | Moderate | AD/atherosclerosis/hemorrhages | Fig. 2d |
| 22-16 | M | 90 | 5.42 | VI | Moderate | AD/atherosclerosis/hemorrhage | Fig. 4 |
| 22-17 | M | 90 | 6.08 | V | Sparse | AD/atherosclerosis/CAA/Lewy bodies (Amygdala) | Fig. 4 |
| 22-18 | F | 89 | 5.25 | VI | Moderate | AD | Fig. 4 |
| 23-11 | M | 71 | 6.2 | IV | Frequent | AD | Fig. 5 (AD7) |
| 24-12 | F | ≥90 | 7.41 | V | Sparse | AD/arterial sclerosis/atherosclerosis/hippocampal sclerosis/solitary infarct | Fig. 2a, b |
| 24-17 | F | ≥90 | 4.43 | VI | Frequent | AD/CAA | Fig. 2d |
| 25-10 | F | 57 | 3.55 | VI | Frequent | AD | Figs. 1d, 2d, and 3c (AD5) |
| 28-11 | M | 81 | 4 | VI | Moderate | AD/CAA/multiple infarctions/trauma | Figs. 1d and 2d |
| 29-15 | M | 83 | 4.73 | V | Moderate | AD/CAA | Fig. 2d, e |
| 3-12 | M | 81 | 5 | IV | Sparse | AD/atherosclerosis | Fig. 2b |
| 3-13 | F | ≥90 | 4.66 | VI | Frequent | AD/diffuse LB/hippocampal sclerosis | Figs. 1d, 2a, b, d, and 3a, c (AD1 for Fig. 3) |
| 3-16 | F | 72 | 5.42 | IV | Frequent | AD | Fig. 2d |
| 30-10 | M | 46 | 5.3 | VI | Moderate | AD/CAA/vascular dementia | Figs. 1d and 2d |
| 31-11 | F | ≥90 | 3.55 | V | Frequent | AD/hippocampal sclerosis | Fig. 2a, b, d |
| 33-09 | M | 93 | 6.36 | VI | Frequent | AD/arteriolar sclerosis/atherosclerosis/CAA | Fig. 4 |
| 33-14 | F | 73 | 5.75 | VI | Frequent | AD | Fig. 2a and b |
| 34-12 | F | ≥90 | 5 | VI | Sparse | AD/CAA/hippocampal sclerosis | Fig. 2d |
| 34-13 | M | 46 | 4.6 | VI | Frequent | AD/CAA/vascular dementia | Fig. 2a and b |
| 37-10 | F | 88 | 5.3 | V | Frequent | AD/subcortical arteriosclerotic leukoencephalopathy | Figs. 2d and 4 |
| 37-12 | M | ≥90 | 5.41 | VI | Moderate | AD/arteriosclerosis/atherosclerosis/micro-hemorrhages | Figs. 1a–d and 2d, e |
| 37-15 | F | 87 | 6.03 | VI | Frequent | AD/atherosclerosis/meningioma | Fig. 4 |
| 38-11 | M | ≥90 | 5.5 | V | Moderate | AD | Figs. 1d and 2a, b, d |
| 42-16 | F | 74 | 4.53 | V | Frequent | AD/CAA/Diffuse LB | Fig. 4 |
| 47-16 | F | ≥90 | 6.92 | VI | Moderate | AD | Figs. 1d and 2d |
| 48-17 | F | 92 | 5.03 | VI | Moderate | AD/atherosclerosis | Figs. 3c, e and 4 |
| 5-13 | F | ≥90 | 4.92 | V | Frequent | AD/atherosclerosis/CAA/vascular dementia | Figs. 1g, 2a, b, d, and 3a, c (AD2 for Fig.3) |
| 6-14 | F | 64 | 6.15 | VI | Moderate | AD | Fig. 2d |
| 8-13 | M | ≥90 | 4.85 | V | Sparse | AD/atherosclerosis/hippocampal sclerosis | Fig. 2d, e |
| 805 | F | ≥90 | 8.5 | V | Frequent | AD/arteriosclerosis/atherosclerosis/CAA | Fig. 1d |
| 811 | M | 59 | 5.5+ | VI | Frequent | AD/CAA/hydrocephalus | Fig. 2a, b, d |
| 813 | M | 79 | 5.75 | V | Frequent | AD/CAA | Fig. 2a, b |
| 869 | F | 75 | 5 | VI | Moderate | AD | Fig. 2a, b |
| 871 | F | 88 | 9 | V | Sparse | AD/CAA/cerebral contusion/hippocampal sclerosis | Fig. 2a, b |
| 9-18 | F | 89 | 4.87 | V | Frequent | AD/ischemic leukoencephalopathy/atherosclerosis/vascular dementia | Fig. 4 |
| 900 | M | 87 | 5.5 | V–VI | Frequent | AD/CAA | Figs. 1d, 1e, f, and 2d |
| 909 | M | 86 | 5.5+ | V | Frequent | AD/CAA/ependymitis | Fig. 2d |
| U1 | F | 96 | 5 | VI | Frequent | AD/CAA/cerebrovascular disease | Fig. 2d |
| U2 | M | 82 | 5 | V–VI | Moderate | AD/CAA/cerebrovascular disease | Figs. 1d and 2a, b |
| 7-11 | F | ≥90 | 4.25 | III | Moderate | CIND/atherosclerosis | Fig. 5 (AD6) |
| Tauopathy | |||||||
| 19-12 | M | ≥90 | 5.91 | III | None | Hippocampal sclerosis | Fig. 5 (T3) |
| 20-12 | F | ≥90 | 7.5 | IV | Sparse | Hippocampal sclerosis | Fig. 5 (T4) |
| 23-12 | F | ≥90 | 6 | III | None | CAA/solitary infarct/hippocampal sclerosis | Fig. 5 (T2) |
| 31-12 | M | ≥90 | 6 | IV | None | Hippocampal sclerosis | Fig. 5 (T5) |
| U3 | M | 75 | 8 | IV | None | NFT-predominant AD/arteriosclerosis/atherosclerosis | Fig. 5 (T1) |
| Controls | |||||||
| 1-13 | M | ≥90 | 6 | I | None | Atherosclerosis/solitary infarct | Fig. 5 (N1) |
| 830 | F | 89 | 4.25 | II | None | AD/vascular dementia/atrophy | Fig. 3a (Con) |
| 907 | M | 84 | 5 | N/A | None | Normal | Fig. 5 (N2) |
Plaques number in the area (based on Bielschowsky stain and IHC): none = 0; sparse = 1–5; moderate = 6–20; frequent = more than 20.
CIND cognitive impairment, no dementia, CAA cerebral amyloid angiopathy.